A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults.

McMahon, Robert; Fuchs, Ulrike; Schneider, Martina; Hadl, Sandra; Hochreiter, Romana; Bitzer, Annegret; Kosulin, Karin; Koren, Michael; Mader, Robert; Zoihsl, Oliver; Wressnigg, Nina; Dubischar, Katrin; Buerger, Vera; Eder-Lingelbach, Susanne; Jaramillo, Juan Carlos

A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults.

McMahon, Robert; Fuchs, Ulrike; Schneider, Martina; Hadl, Sandra; Hochreiter, Romana; Bitzer, Annegret; Kosulin, Karin; Koren, Michael; Mader, Robert; Zoihsl, Oliver; Wressnigg, Nina; Dubischar, Katrin; Buerger, Vera; Eder-Lingelbach, Susanne; Jaramillo, Juan Carlos.

Afiliação

McMahon R; Valneva Austria GmbH, 1030 Vienna, Austria.
Fuchs U; Valneva Austria GmbH, 1030 Vienna, Austria.
Schneider M; Valneva Austria GmbH, 1030 Vienna, Austria.
Hadl S; Valneva Austria GmbH, 1030 Vienna, Austria.
Hochreiter R; Valneva Austria GmbH, 1030 Vienna, Austria.
Bitzer A; Valneva Austria GmbH, 1030 Vienna, Austria.
Kosulin K; Valneva Austria GmbH, 1030 Vienna, Austria.
Koren M; Walter Reed Army Institute of Research, Bethesda, MD, USA.
Mader R; CRETA GmbH, Campus Vienna Biocenter 3, 1030 Vienna, Austria.
Zoihsl O; Valneva Austria GmbH, 1030 Vienna, Austria.
Wressnigg N; Valneva Austria GmbH, 1030 Vienna, Austria.
Dubischar K; Valneva Austria GmbH, 1030 Vienna, Austria.
Buerger V; Valneva Austria GmbH, 1030 Vienna, Austria.
Eder-Lingelbach S; Valneva Austria GmbH, 1030 Vienna, Austria.
Jaramillo JC; Valneva Austria GmbH, 1030 Vienna, Austria.

J Travel Med ; 31(2)2024 Mar 01.

Article em En | MEDLINE | ID: mdl-38091981

Assuntos

Febre de Chikungunya; Vírus Chikungunya; Adulto; Humanos; Anticorpos Neutralizantes; Anticorpos Antivirais; Febre de Chikungunya/prevenção & controle; Método Duplo-Cego; Testes de Neutralização; Vacinas Atenuadas; Adolescente; Adulto Jovem; Pessoa de Meia-Idade

Palavras-chave

Chikungunya virus; Phase 3; immunogenicity; safety; vaccine

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vírus Chikungunya / Febre de Chikungunya Limite: Adolescent / Adult / Humans / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google